Physician profile
Donovan Nembhard
NPI 1639184351
$3,482.11
in general payments reported to CMS, 2019-2025
36 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $412 · 2021: $595 · 2022: $410 · 2023: $702 · 2024: $312 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.85 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $965.85 | 2019-2022 | |
| Astellas Pharma US INC | $445.40 | 2019-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $293.10 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $201.61 | 2021-2025 | Rexulti, Jynarque |
| Novartis Pharmaceuticals Corporation | $177.81 | 2019-2024 | |
| Pfizer INC. | $144.95 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $129.27 | 2019-2022 | |
| Angiodynamics, INC. | $121.26 | 2021 | |
| Exact Sciences Corporation | $93.34 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $83.68 | 2021-2023 | Gvoke Hypopen |
| Lilly USA, LLC | $69.87 | 2020-2023 | Trulicity |
| Intuitive Surgical, INC. | $68.63 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $55.35 | 2019-2023 | Kristalose |
| Aimmune Therapeutics, INC. | $49.28 | 2024 | |
| Cmp Pharma, INC. | $40.37 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $38.05 | 2024 | |
| Eisai INC. | $35.79 | 2021 | |
| Biogen, INC. | $35.65 | 2021-2022 | |
| Nevro Corp. | $33.73 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $33.38 | 2021 | |
| Acella Pharmaceuticals, LLC | $32.26 | 2024-2025 | NP Thyroid 60 |
| Intra-Sana Laboratories | $29.01 | 2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Neurocrine Biosciences, INC. | $27.74 | 2024 | Ingrezza |
| Novo Nordisk INC | $27.47 | 2025 | Wegovy |
| Harmony Biosciences LLC | $27.16 | 2021 | |
| Mylan Specialty L.P. | $24.22 | 2020 | |
| Mdd US Operations, LLC | $22.01 | 2020 | |
| Horizon Therapeutics Plc | $21.96 | 2023 | Krystexxa |
| Ibsa Pharma INC. | $21.72 | 2020 | |
| Bsn Medical INC | $20.35 | 2022 | |
| Amgen INC. | $19.37 | 2021 | |
| Smith+Nephew, INC. | $19.32 | 2022 | |
| Avanir Pharmaceuticals, INC. | $19.01 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $18.80 | 2023 | Bard Urinary Drainage Bag |
| Linus Health, INC. | $18.25 | 2023 | |
| Sun Pharmaceutical Industries INC. | $17.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donovan Nembhard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.